Related Experiment Video
Updated: Jul 4, 2026
09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
[Monoclonal antibodies. Principles, generation, application, and side effects]
1Institut für Klinische Immunologie und Transfusionsmedizin, Medizinische Fakultät, Universität Leipzig, Johannisallee 30, 04103, Leipzig, Germany. ulrich.sack@medizin.uni-leipzig.de
Der Internist
|July 1, 2008
Summary
Monoclonal antibodies are key in internal medicine for treating chronic and malignant diseases. Advances in biotechnology ensure their safe and effective use, with more therapeutic options on the horizon.
Area of Science:
- Biotechnology
- Immunology
- Internal Medicine
Context:
- Monoclonal antibodies (mAbs) are increasingly vital in internal medicine.
- Their application targets cell surface receptors and cytokines for specific therapies.
- This is particularly relevant for chronic and malignant diseases.
Purpose:
- To highlight the growing importance and application of monoclonal antibodies in medicine.
- To discuss the biotechnological production processes of antibody preparations.
- To underscore the safety and future potential of these therapeutic agents.
Summary:
- Monoclonal antibodies are integral to modern internal medicine, enabling targeted therapies for complex diseases.
- Biotechnological advancements facilitate the production of these antibodies, maintaining specificity.
- Despite complex antigen structures, severe side effects are rare, especially with humanized antibodies.
Impact:
- Monoclonal antibody therapies offer precise treatment options for chronic and malignant conditions.
- The continued development of these antibodies promises expanded diagnostic and therapeutic capabilities.
- Enhanced safety profiles of humanized antibodies improve patient outcomes and treatment accessibility.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:25Antibody Structure and Classes
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.